<DOC>
	<DOCNO>NCT01624285</DOCNO>
	<brief_summary>The purpose study determine sorafenib ( sorafenib tosylate ) safe effective treatment option prevent liver cancer high risk patient follow liver transplantation . Liver transplantation treatment option liver cancer patient , despite transplantation , liver cancer recur new , transplant liver . It know whether sorafenib effective preventing cancer recurrence high risk patient follow liver transplantation</brief_summary>
	<brief_title>Sorafenib Tosylate Following Liver Transplant Treating Patients With Liver Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Two-year recurrence free survival ( RFS ) . SECONDARY OBJECTIVES : I . One-year recurrence free survival . II . Overall survival ( OS ) . III . Safety . IV . Impact drug-drug interaction ( i.e . immunosuppression agent ) . V. Impact biomarkers ( alpha-fetoprotein [ AFP ] , protein-induced vitamin K absence antagonist II [ PIVKA II ] ) . VI . Effects therapy wound heal . VII . Impact hepatitis C viral recurrence . OUTLINE : Patients randomize 1 2 treatment arm . ARM I : Patients receive sorafenib tosylate orally ( PO ) twice daily ( BID ) . ARM II : Patients receive placebo PO BID . In arm treatment continue 24 month absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 6 month 2 year .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Patients must hepatocellular carcinoma ( HCC ) one follow explant : microvascular/macrovascular invasion , tumor outside Milan criterion , poor tumor differentiation ; patient macrovascular invasion explant pathology stratify * Additionally , follow include ** Patients elevate surrogate marker ( AFP &gt; 500 PIVKA &gt; 400 ) pre transplant biopsy proven HCC prior orthotopic liver transplantation ( OLT ) explant Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 02 Patients life expectancy &gt; 12 week Patients must complete prednisone taper within 6 week post OLT Patients must enrol 6 12 week post OLT Cadaveric donor ( live donor liver transplantation [ LDLT ] donor cardiac death transplantation [ DCDT ] ) No sorafenib prior inclusion study Platelet count &gt; 50 x 10^9/L Hemoglobin &gt; = 8.5 g/dL Total bilirubin = &lt; 5 mg/dL Alanine transaminase ( ALT ) aspartate aminotransferase ( AST ) = &lt; 5 x upper limit normal Amylase lipase = &lt; 1.5 x upper limit normal Serum creatinine &lt; 2 x upper limit normal Prothrombin time ( PT ) = &lt; 6 second international normalized ratio ( INR ) = &lt; 2.3 AFP &gt; 500 ( pretransplant ) PIVKA &gt; 400 ( pretransplant ) Patient receive prior antiangiogenic therapy , systemic target agent systemic chemotherapy * Prior surgical resection , chemoembolization local therapy prior transplant permit Women childbearing potential must negative serum pregnancy test perform within 7 day prior start study drug ; postmenopausal woman ( defined menses least 1 year ) surgically sterilize woman require undergo pregnancy test Patients ( men woman ) childbearing potential must agree use adequate contraception begin sign informed consent form ( ICF ) least 30 day last dose study drug ; definition adequate contraception base judgment principal investigator designate associate Patient must able swallow retain oral medication Patient must exhibit ability understand willingness sign write informed consent regard study alternative treatment Significant ongoing immunologic rejection base pathology clinical diagnosis ( time transplant randomization ) Use T cell deplete agent prevention treatment rejection point prior enrollment study Patient document evidence metastatic disease 100 % tumor necrosis explant pathology Use mammalian target rapamycin ( mTOR ) inhibitor prior transplant posttransplant immunosuppression Use alemtuzumab Living donor liver transplant ( LDLT ) donation cardiac death transplant ( DCDT ) Human immunodeficiency virus ( HIV ) positive patient Hepatitis C virus ( HCV ) recurrence time randomization Use direct acting antiviral HCV recurrence Requirement retransplantation primary non function Uncontrolled hypertension , define systolic blood pressure &gt; 140 mmHg diastolic pressure &gt; 90 mmHg , despite optimal medical management Active clinically significant cardiac disease include : Congestive heart failure New York Heart Association ( NYHA ) &gt; class II Coronary artery disease Cardiac arrhythmia require antiarrhythmic therapy beta blocker digoxin Unstable angina newonset angina within 3 month randomization , myocardial infarction ( MI ) within 6 month randomization Clinically active serious infection document positive culture incomplete course treatment bacteremia fungemia Evidence history bleed diathesis coagulopathy Patients pulmonary hemorrhage/bleeding event grade 2 high within 4 week randomization Patients thrombotic , embolic , venous , arterial event , cerebrovascular accident ( include transient ischemic attack [ TIAs ] ) within 6 month randomization Prior use rafkinase inhibitor ( sorafenib ) , vascular endothelial growth factor ( VEGF ) inhibitor , mitogenactivated protein kinase ( MAPK ) /extracellularsignalrelated kinase ( ERK ) kinase ( MEK ) inhibitor , farnesyl transferase inhibitor Patients use cytochrome P450 3A4 ( CYP3A4 ) inducer ( eg , phenytoin , carbamazepine , phenobarbital , St. John 's Wort dexamethasone ) dose great 16 mg daily , rifampin and/or rifabutin within 28 day randomization Patients nonHCC malignancy except DCIS ( ductal carcinoma situ ) , cervical cancer insitu , basal cell superficial bladder tumor ; patient survive cancer curatively treat without evidence recurrence 3 year randomization allow Presence nonhealing wound , nonhealing ulcer , bone fracture Known suspect allergy hypersensitivity study drug , study drug class , excipients formulation give course trial Any malabsorption condition Women pregnant breastfeeding Inability comply protocol and/or willing available followup assessment Patients fibrolamellar HCC , cholangiocarcinoma , combine HCCcholangiocarcinoma Any condition , investigator 's opinion , make patient unsuitable trial participation Prior use systemic chemotherapy HCC Prior use systemic investigational agent HCC Prior use rafkinase inhibitor ( sorafenib ) , VEGF inhibitor , MEK inhibitor farnesyl transferase inhibitor Use biologic response modifier , granulocyte colonystimulating factor ( GCSF ) , permit within 3 week prior study entry ; GCSF hematopoietic growth factor may use management acute toxicity , febrile neutropenia , clinically indicate discretion investigator ; however , may administer prevent dose reduction ; patient take chronic erythropoietin permit , provide dose adjustment undertaken within 1 month prior randomization study Autologous bone marrow transplant stem cell rescue within four month start study drug Concomitant treatment rifampin St. John 's wort Concomitant oral mTOR inhibitor treatment Use direct acting antiviral HCV recurrence Use Tcell deplete agent Use alemtuzumab Anticoagulation , describe , allow : VitaminK antagonist ( e.g. , warfarin ) ** Low dose warfarin ( 1 mg orally , daily ) PTINR = &lt; 1.5 x ULN permit ; patient take concomitant warfarin monitor regularly change PT , PTINR clinical bleed episode Low dose aspirin ( = &lt; 100 mg daily ) . Heparins heparinoids Use investigational drug</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>